Compare SA & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SA | RCUS |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.1B |
| IPO Year | N/A | 2018 |
| Metric | SA | RCUS |
|---|---|---|
| Price | $28.56 | $21.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $65.00 | $29.38 |
| AVG Volume (30 Days) | 1.0M | ★ 2.1M |
| Earning Date | 11-12-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $240,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.40 | $6.50 |
| 52 Week High | $31.35 | $26.40 |
| Indicator | SA | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 56.70 | 42.60 |
| Support Level | $27.78 | $20.35 |
| Resistance Level | $31.19 | $26.10 |
| Average True Range (ATR) | 1.40 | 1.48 |
| MACD | 0.04 | -0.59 |
| Stochastic Oscillator | 57.60 | 18.43 |
Seabridge Gold Inc is a development stage company involved in the exploration, and development of gold properties sited in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, and Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.